Cerus (CERS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.01
- Estimate
- -$0.01
- Surprise
- —
- Revenue (period 2026-06-30)
- $57.4M
- Score today
- 5.4/10
Revenue source: mixed.
How the report landed
Cerus (CERS) reported adjusted EPS of -$0.01, in line with the -$0.01 estimate.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CERS Sell at 5.4/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-02.
What argues against it
- Concentration risk — Supplier: Fresenius Kabi
- Concentration risk — Customer: American Red Cross
- Quality below floor (3.1 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $2.42
- Price target
- $4.36
- Stop
- $2.25
- Upside to target
- +80.5%
- Reward-to-risk
- 6.6:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
CERS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $487.7M
- P/E (fwd)
- -484.0
- 52-week range
- $1.38–$3.47
- Off 52-week high
- 30.4%
- RSI (14)
- 60
- Volume vs avg
- 0.07×
- Score today
- 5.4/10